Home Business Aidi Pharmaceuticals: plans to transfer 100 million yuan to transfer the technical secrets and patent rights of the new anti-tumor drug ACC006 project_ 东方富网

Aidi Pharmaceuticals: plans to transfer 100 million yuan to transfer the technical secrets and patent rights of the new anti-tumor drug ACC006 project_ 东方富网

by admin

Summary

[Aidi Pharmaceuticals: plans to transfer 100 million yuan to transfer the technical secrets and patent rights of the new anti-tumor drug ACC006 project]Aidi Pharmaceuticals (688488) announced on the evening of December 24 that the company and its subsidiary Arcelite intend to cooperate Xin Biology signed the “Technology Transfer Contract” for the company’s new anti-tumor drug ACC006 project. The company and Arcelite transferred all the rights and interests related to the technical secrets and patent rights of the target project to Lixin Biology, and Lixin Biology received the subject matter. The project also paid 100 million yuan (tax included) for technology transfer. (Securities Times)


  Addison Pharmaceutical(688488) Evening of December 24announcement, The company and its subsidiary Arcelite intends to sign a “technology transfercontract》, the company and Arcelite transfer all the rights and interests related to the technical secrets and patent rights of the target project it owns to Lixin Bio, and Lixin Bio will transfer the target project and pay a technology transfer fee of 100 million yuan (tax included). In addition, Li Wenquan and Hu Xionglin, the company’s technical director and core technical personnel, recently applied to resign from the company’s technical director and core technical personnel due to personal reasons. The resignation of the above-mentioned personnel will not affect the company’s production and operation and project research and development, and will not affect the company’s core technology and research and development work.

(Article Source:SecuritiesTimes)


Article source: Securities Times

Editor in charge: 43

See also  The title of the most admired Chinese company in 2021 will drop from CRRC's three-time champion Huawei to second-Top 10

Original title: Aidi Pharmaceuticals: plans to transfer 100 million yuan to transfer the technical secrets and patent rights of the new anti-tumor drug ACC006 project

Solemnly declare: The purpose of this information released by Oriental Fortune.com is to spread more information and has nothing to do with this stand.

report

Share to WeChat Moments

Open WeChat,

Click “Discover” at the bottom

Use “Scan”

You can share the webpage to Moments


Scan the QR code to follow

Oriental Wealth Official Website WeChat

.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy